• In May 2026, Natera, Inc. received FDA approval for Signatera CDx as the first blood-based minimal residual disease companion diagnostic to guide adjuvant atezolizumab (Tecentriq) immunotherapy decisions in muscle-invasive bladder cancer, following the Phase III IMvigor011 trial and supported by extensive clinical evidence and Medicare coverage across multiple cancers.
• This decision highlights how MRD-guided care can personalize treatment by identifying which bladder cancer patients may benefit from immunotherapy while sparing MRD‑negative patients unnecessary adjuvant therapy.
• Now we will examine how this first-in-class blood-based MRD companion diagnostic approval may reshape Natera’s investment narrative in precision oncology.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Natera Investment Narrative Recap

To own Natera you need to believe that minimal residual disease testing and broader molecular diagnostics can become central tools in routine cancer care, and that Natera can translate scientific validation into profitable scale despite ongoing losses. The new FDA approval for Signatera CDx reinforces MRD as a real clinical decision tool, and may strengthen the near term oncology catalyst, but it does not remove the core risk around high spending and the path to sustainable profitability.

Among recent announcements, the May 2026 decision to raise full year revenue guidance to US$2.74 billion to US$2.82 billion stands out in light of the Signatera CDx approval. Higher expected revenue alongside a widened net loss in Q1 underlines the central tension in the Natera story: strong top line momentum in oncology and women’s health versus continued heavy investment in trials, AI and commercialization that keeps profitability out of reach for now.

Yet beneath the clinical win, investors should also be aware of growing legal and regulatory pressures that...

Natera's narrative projects $3.8 billion revenue and $129.1 million earnings by 2029.

Uncover how Natera's forecasts yield a $259.11 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Some analysts were already assuming about 23% annual revenue growth and roughly US$695 million in earnings by 2029, so this approval could either validate that optimism or force you to reconsider how aggressive those expectations really are.

Explore 5 other fair value estimates on Natera - why the stock might be worth as much as 56% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 43 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.